These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 23016985

  • 1. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J, De la Rosa AJ, Docobo F, García-Carbonero R, Padillo FJ.
    Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 3. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Feb; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 4. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 5. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O.
    Medicina (Kaunas); 2019 Nov 21; 55(12):. PubMed ID: 31766556
    [Abstract] [Full Text] [Related]

  • 6. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.
    Tanaka S, Arii S.
    Int J Clin Oncol; 2010 Jun 21; 15(3):235-41. PubMed ID: 20505971
    [Abstract] [Full Text] [Related]

  • 7. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Oseini AM, Roberts LR.
    Expert Opin Ther Targets; 2009 Apr 21; 13(4):443-54. PubMed ID: 19335066
    [Abstract] [Full Text] [Related]

  • 8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 9. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
    Kim S, Abou-Alfa GK.
    Clin Adv Hematol Oncol; 2014 Jan 14; 12(1):36-41. PubMed ID: 25000314
    [Abstract] [Full Text] [Related]

  • 10. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, Luu DA, Jong CT, Lam IW.
    Anticancer Agents Med Chem; 2011 Jul 14; 11(6):560-75. PubMed ID: 21554207
    [Abstract] [Full Text] [Related]

  • 11. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL, Yeo W.
    J Gastroenterol Hepatol; 2012 May 14; 27(5):862-72. PubMed ID: 22369685
    [Abstract] [Full Text] [Related]

  • 12. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
    Tong X, Wang Q, Wu D, Bao L, Yin T, Chen H.
    Biochem Biophys Res Commun; 2020 Feb 26; 523(1):147-152. PubMed ID: 31836141
    [Abstract] [Full Text] [Related]

  • 13. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 26; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 14. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.
    Kudo M.
    Int J Clin Oncol; 2010 Jun 26; 15(3):242-55. PubMed ID: 20509038
    [Abstract] [Full Text] [Related]

  • 15. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q, Lui VW, Yeo W.
    Future Oncol; 2011 Oct 26; 7(10):1149-67. PubMed ID: 21992728
    [Abstract] [Full Text] [Related]

  • 16. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
    Breunig C, Mueller BJ, Umansky L, Wahl K, Hoffmann K, Lehner F, Manns MP, Bantel H, Falk CS.
    Clin Cancer Res; 2014 May 01; 20(9):2410-23. PubMed ID: 24573550
    [Abstract] [Full Text] [Related]

  • 17. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 01; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W.
    World J Gastroenterol; 2015 Nov 14; 21(42):12059-70. PubMed ID: 26576091
    [Abstract] [Full Text] [Related]

  • 19. Signaling pathways in hepatocellular carcinoma.
    Sia D, Villanueva A.
    Oncology; 2011 Nov 14; 81 Suppl 1():18-23. PubMed ID: 22212931
    [Abstract] [Full Text] [Related]

  • 20. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.